Acadia Pharmaceuticals’ DAYBUE gets FDA approval for Rett syndrome
The FDA approval of DAYBUE was based on the LAVENDER phase 3 study that evaluated the efficacy and…
We use them to give you the best experience. If you continue using our website, we'll assume that you are happy to receive all cookies on this website.
ContinueLearn More X
13 Mar 23
The FDA approval of DAYBUE was based on the LAVENDER phase 3 study that evaluated the efficacy and…
08 Mar 23
This year's Top 30 Women in Food list highlights the Women who are redefining what it means to…
Brand Protection and Anti-counterfeitingCleaning and Disinfection
08 Mar 23
Designed to help nutrition leaders capitalise on the opportunities presented by emerging technologies and trends, the Future of…
06 Mar 23
The sBLA of the drug candidate is backed by the results from the Clarity AD trial in which…
02 Mar 23
The lawsuit claims that Biogen is still obligated to pay royalties for all the Tysabri that was manufactured…
01 Mar 23
The approval was based on findings from the SAPHYR phase 3 clinical trial in which 28% of patients…
28 Feb 23
Mayne’s portfolio to be acquired comprises around 45 commercial products, four pipeline products and 40 regulatory-approved non-marketed products,…
28 Feb 23
Seagen has developed drugs like Adcetris, Tivdak, and Padcev based on its proprietary ADC technology
27 Feb 23
The positive opinion was adopted on the basis of a phase 3 trial that showed superior survival outcomes…
24 Feb 23
Previously referred to as efanesoctocog alfa, ALTUVIIIO is approved for routine prophylaxis and on-demand treatment to control bleeding…